Showing results (1601-1610 of 2,088) with videos related to

Sort By:
Pageof 209
Cellular Microbiology|April 11, 2015
Reprogramming of myeloid angiogenic cells by Bartonella henselae leads to microenvironmental regulation of pathological angiogenesisFiona O'Rourke, Tanja Mändle, Carmen Urbich, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|April 17, 2023
Electrocardiographic markers of subclinical atrial fibrillation detected by implantable loop recorder: insights from the LOOP StudyLucas Yixi Xing, Søren Zöga Diederichsen, Søren Højberg, et al.
Frontiers in Oncology|October 2, 2023
Case Report: Mycosis fungoides as an exclusive manifestation of common variable immunodeficiency in a family with a NFKB2 gene mutationMaría Noel Spangenberg, Sofía Grille, Camila Simoes, et al.
American Heart Journal|April 17, 2025
Rationale and design of the anticoagulant therapy after left atrial appendage closure (ATLAAC) trialKristina Gosvig, Julie Goller, Nils Henrik Hansson, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
SIRT5-dependent regulation of ASL controls arginine metabolism and T cell functionKim Han, Rachael J Klein, Kaiyuan Wu, et al.
Frontiers in Physiology|December 19, 2022
Endothelial deletion of the cytochrome P450 reductase leads to cardiac remodellingMelina Lopez, Pedro F Malacarne, Deepak P Ramanujam, et al.
The Journal of Biological Chemistry|September 10, 2010
Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53A R M Ruhul Amin, Dongsheng Wang, Hongzheng Zhang, et al.
Cancer Metastasis Reviews|December 31, 2013
Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicineSarah Derks, Arjen H G Cleven, Veerle Melotte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2008
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patientsAlba A Brandes, Enrico Franceschi, Alicia Tosoni, et al.
Pageof 209